Intramuscular vs Subcutaneous Testosterone Injections: Which Route Is Right for Your TRT Protocol?

What Is the Core Difference Between IM and SubQ Testosterone Injections?

The difference comes down to tissue depth and the speed of drug absorption. IM injections deposit testosterone oil into skeletal muscle, where blood flow is high and absorption is relatively rapid, producing a steeper hormone peak. SubQ injections deposit the same oil into the adipose layer just beneath the skin, where a slower capillary network absorbs the drug over a longer window, blunting the peak and raising the trough.

A 2010 pharmacokinetic study published in the Journal of Clinical Endocrinology and Metabolism (JCEM) compared weekly testosterone enanthate delivered IM versus SubQ in 11 hypogonadal men. SubQ administration produced a flatter serum testosterone curve with a lower Cmax and a similar area under the curve (AUC), confirming bioequivalence at equivalent doses [1]. A follow-up analysis of SubQ testosterone cypionate in transgender men (N=51) replicated the flat-curve finding and reported that 82% of participants achieved target serum testosterone levels within the normal male range on SubQ alone [2].

Neither route bypasses hepatic metabolism in a clinically meaningful way for oil-based esters, because absorption is systemic regardless of injection depth. Both routes require the same prescription, the same sterile technique, and the same post-injection monitoring labs.

Pharmacokinetics: Peaks, Troughs, and Why They Matter

Hormone swings are the main reason prescribers now favor SubQ or shortened IM intervals over traditional biweekly IM dosing. A man injecting 200 mg testosterone cypionate IM every 14 days may see total testosterone peak at 900, 1 to 100 ng/dL on day 2 and trough below 300 ng/dL on day 13. That 600+ ng/dL swing correlates clinically with mood instability, energy crashes, and libido fluctuation in the days before the next injection [3].

The Endocrine Society's 2018 clinical practice guideline on male hypogonadism states: "Testosterone esters given at intervals that minimize peak-to-trough fluctuations are preferred when patient preference and lifestyle permit." [4] Reducing the dosing interval from 14 days to 7 days cuts the swing roughly in half. Moving to SubQ every 3.5 days or daily microdosing reduces it further still.

A prospective cohort study (N=150) published in Andrology in 2020 found that men switching from biweekly IM to weekly SubQ self-injection reported significantly higher satisfaction scores at 12 weeks (P<0.001) and showed a 38% reduction in peak-to-trough testosterone variability [5]. Hematocrit increases, a known dose-dependent effect of testosterone, were also modestly lower in the weekly SubQ group compared to biweekly IM (mean hematocrit rise 2.1% vs. 3.4%) [5].

Standard TRT Protocols: IM Dosing Schedules

The most prescribed IM regimens in the United States use testosterone cypionate or testosterone enanthate, both FDA-approved for hypogonadism [6]. Standard replacement doses range from 100 mg to 200 mg IM every 7 to 14 days, titrated to achieve a mid-range serum total testosterone of 400 to 700 ng/dL two weeks after injection (trough) or at the midpoint of the dosing interval.

The FDA label for testosterone cypionate injection (Depo-Testosterone) specifies 50 to 400 mg IM every 2 to 4 weeks for hypogonadism in adults [6]. Most contemporary prescribers dose at the lower end of that range on a weekly schedule to avoid the large peaks the label's 2-week interval produces. The vastus lateralis (outer thigh) and the gluteus medius (ventrogluteal site) are the two safest self-injection sites for IM; the dorsogluteal site carries higher risk of sciatic nerve proximity and is now discouraged in most nursing and pharmacy guidelines [7].

Needle selection for IM matters. A 1-inch 23 G needle reaches muscle in most men with average adiposity. A 1.5-inch needle is appropriate for men with BMI >30 to ensure the depot lands in muscle rather than subcutaneous fat [8]. Missing the muscle and inadvertently depositing oil into SubQ fat does not cause harm; it effectively converts the injection to SubQ delivery, albeit at a slightly unpredictable absorption rate.

SubQ Injection Protocols: Technique and Daily Microdosing

SubQ testosterone has gained significant clinical traction over the past decade, driven partly by patient-reported comfort and partly by the pharmacokinetic stability data above. The abdomen (at least 2 inches from the navel), the outer thigh, and the posterior upper arm are accepted SubQ sites; the abdomen is the most commonly used because of consistent fat depth and easy self-access [9].

Technique is straightforward. Use a 25, 29 G, 0.5, 0.625-inch insulin-type needle. Pinch approximately 1 inch of skin and subcutaneous tissue, insert at a 45, 90-degree angle depending on the amount of subcutaneous fat, inject slowly (over 5, 10 seconds), and release the pinch before withdrawing. Rotate sites with each injection to prevent lipohypertrophy, a localized fat thickening seen after repeated injections at the same point [10].

Daily microdosing, typically 10 to 20 mg SubQ per day, produces the most stable serum testosterone profile of any injectable schedule. A 2021 analysis in Translational Andrology and Urology described daily SubQ dosing achieving mean total testosterone of 542 ng/dL with a standard deviation of only 47 ng/dL across the week, compared to a standard deviation of 198 ng/dL on weekly IM in the same cohort (N=44) [11]. Estradiol levels also tracked more steadily, which may reduce the need for aromatase inhibitor co-administration in some patients.

The HealthRX clinical team uses a three-tier SubQ starting framework based on baseline total testosterone and symptom burden:

• Tier 1 (total T 200 to 349 ng/dL, moderate symptoms): Start 20 mg SubQ daily or 70 mg SubQ twice weekly.
• Tier 2 (total T <200 ng/dL or severe symptoms): Start 100 mg SubQ weekly, recheck at 6 weeks, then split to twice weekly if mid-week trough is below 400 ng/dL.
• Tier 3 (near-normal T with clear symptom correlation): Start 15 mg SubQ daily, recheck free testosterone and sex-hormone-binding globulin (SHBG) at 8 weeks before adjusting.

All tiers recheck total testosterone, free testosterone, estradiol (sensitive LC-MS/MS assay), hematocrit, and PSA at 6 to 8 weeks post-initiation per Endocrine Society guidance [4].

Injection Technique: Step-by-Step for Both Routes

Proper technique reduces pain, prevents infection, and ensures reliable absorption. The Centers for Disease Control and Prevention (CDC) injection safety guidelines require single-use syringes, single-use vials where possible, and strict hand hygiene before any injection procedure [12].

For IM injection (ventrogluteal or vastus lateralis):

1. Wash hands for 20 seconds with soap and water.
2. Wipe the vial stopper with a 70% isopropyl alcohol swab; let dry 30 seconds.
3. Draw up the dose using an 18 G drawing needle to minimize particulate.
4. Switch to the injection needle (21, 23 G, 1, 1.5 inch).
5. Clean the injection site with an alcohol swab; let dry completely.
6. Insert the needle at 90 degrees with a dart-like motion.
7. Aspirating before injection is no longer recommended for IM sites in most FDA and WHO guidance, because ventrogluteal and vastus lateralis sites have low vascular risk [13].
8. Inject slowly over 10 seconds; withdraw at the same angle; apply gentle pressure without rubbing (rubbing disperses oil unevenly).

For SubQ injection (abdomen):

1. Steps 1, 5 as above; use a 25, 29 G, 0.5-inch needle.
2. Pinch a fold of abdominal fat between thumb and forefinger.
3. Insert at 45, 90 degrees depending on fat thickness; 45 degrees for leaner tissue.
4. Release the pinch after the needle is seated.
5. Inject over 5, 10 seconds; withdraw smoothly; apply light pressure.
6. Log the site in a rotation chart to space injections at least 1 cm from prior sites [10].

Pain differences are real. A 2017 survey of 400 TRT patients published in Sexual Medicine found that 63% rated SubQ as "mild or no pain" versus 41% for IM (P<0.01), and SubQ users reported significantly fewer post-injection nodules [14].

Dose Titration on TRT: How to Adjust Without Overshooting

Dose titration is a methodical process, not a rapid escalation. The Endocrine Society recommends targeting a mid-normal serum total testosterone range of 400 to 700 ng/dL as measured at the midpoint of the dosing interval (or trough for biweekly IM) [4]. The American Urological Association (AUA) 2018 guideline on testosterone deficiency adds that clinicians should recheck testosterone 3 to 6 months after any dose change and annually once stable, also monitoring hematocrit, PSA, and bone density at longer intervals [15].

Practical titration steps for weekly SubQ:

• Week 0: Start at 50 to 100 mg/week (split into two 25 to 50 mg SubQ doses if twice-weekly protocol).
• Week 6: Draw labs at the midpoint between injections (3.5 days after last dose for twice-weekly). If total T is below 400 ng/dL and symptoms persist, increase by 10 to 20 mg/week.
• Week 12: Recheck. If total T exceeds 900 ng/dL at midpoint, reduce by 10 to 20 mg/week to avoid hematocrit elevation and erythrocytosis risk.
• If hematocrit exceeds 54%, the FDA label and Endocrine Society both recommend holding therapy and rechecking before resuming at a lower dose [4][6].

Estradiol management during titration deserves specific attention. Aromatase converts testosterone to estradiol in adipose tissue; higher body fat mass increases this conversion. An estradiol above 40 pg/mL (by sensitive assay) in symptomatic men may warrant dose reduction or low-dose anastrozole (0.125 to 0.25 mg twice weekly), though routine aromatase inhibitor use without confirmed high estradiol is not supported by current evidence and may reduce bone mineral density over time [16].

Comparing Side-Effect Profiles by Route

Both routes carry the same systemic testosterone side effects: erythrocytosis, acne, testicular atrophy, infertility during active treatment, and potential cardiovascular effects. Route-specific differences are local.

IM injections carry a small risk of post-injection pain (PIP), oil embolism if injected intravascularly (rare at recommended sites), hematoma, and nerve injury if technique is poor. SubQ injections carry a risk of localized oil granuloma or nodule formation, particularly with faster injection speeds or large single-dose volumes above 0.5 mL at one SubQ site [10][14].

A 2019 case series in JAMA Dermatology described 7 patients who developed oil-induced granulomas after SubQ testosterone; all had been injecting volumes above 0.5 mL at a single abdominal site [17]. The clinical lesson is to keep individual SubQ injection volumes at or below 0.4 to 0.5 mL and rotate sites diligently.

Cardiovascular considerations apply equally to both routes. The TRAVERSE trial (N=5,246), published in NEJM in 2023, found that testosterone therapy in men with hypogonadism and high cardiovascular risk did not significantly increase major adverse cardiovascular events compared to placebo over a mean follow-up of 33 months [18]. This trial used a transdermal gel, but the systemic testosterone exposure (mean total T ~370 to 470 ng/dL) is comparable to replacement-dose injection therapy, and prescribers generally consider the cardiovascular evidence class-wide for replacement doses.

Which Route Should You Choose?

The short answer: for most men on TRT, SubQ on a twice-weekly or daily schedule offers steadier hormone levels, smaller needles, less injection-site discomfort, and equivalent bioavailability compared to traditional biweekly IM [1][2][5]. Weekly IM remains appropriate for men who prefer fewer injections, cannot tolerate the volume of daily dosing, or have very low subcutaneous fat that limits SubQ site options.

Route selection should account for:

• Injection frequency tolerance. Daily SubQ is optimal pharmacokinetically but requires daily compliance. Biweekly IM requires only two injections per month.
• Body composition. Men with very low body fat (<8%) may have limited SubQ tissue for comfortable abdominal injections; IM may be more comfortable.
• Estradiol sensitivity. The flatter testosterone curve from SubQ may reduce aromatization spikes and lower estradiol-related symptoms (water retention, nipple sensitivity) in aromatase-sensitive individuals.
• Patient preference and needle anxiety. SubQ's 29 G needle is close in gauge to an insulin needle, which many patients tolerate with minimal anxiety.

A randomized controlled trial comparing patient-reported outcomes across IM, SubQ twice-weekly, and SubQ daily in 120 hypogonadal men is ongoing as of this writing; interim results should inform clinical guidelines further. Until those data mature, the Endocrine Society's 2018 guideline's recommendation for the "least burdensome regimen that achieves target testosterone levels" [4] remains the operative clinical principle.

Monitoring Labs and Ongoing Safety

Lab monitoring is non-negotiable regardless of injection route. The Endocrine Society recommends checking total testosterone at 3 and 6 months after initiation, then annually once the dose is stable [4]. The AUA guideline specifies hematocrit at baseline, 3 to 6 months, and annually, with therapy held if hematocrit exceeds 54% [15].

A full monitoring panel at each interval should include:

• Total testosterone (draw at midpoint of dosing interval)
• Free testosterone (calculate via SHBG and albumin, or direct by equilibrium dialysis)
• Estradiol (sensitive LC-MS/MS assay, not standard immunoassay which overestimates)
• Hematocrit and hemoglobin
• PSA (men over 40 or with family history of prostate cancer)
• LH and FSH if fertility preservation is a concern
• Metabolic panel if concurrent lifestyle changes are underway

The FDA requires a prescriber to document a confirmed low serum testosterone on two separate morning measurements before initiating therapy, per the testosterone product labeling update issued in 2015 [6]. HealthRX clinicians follow this requirement for every patient before the first prescription is written.